.
MergerLinks Header Logo

Announced

Completed

B Capital led a $100m Series A round in Triumvira Immunologics.

Financials

Edit Data
Transaction Value£76m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Acquisition

Completed

Cross Border

Private Equity

Health Care Facilities

Venture Capital

allogeneic cell therapies

Minority

Friendly

Private

clinical-stage

Synopsis

Edit

B Capital, a multi-stage global investment firm, led a $100m Series A round in Triumvira Immunologics, a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics, with participation from ATEM Capital, Myeloma Investment Fund, Leaps by Bayer, and Northpond Ventures. "We would like to welcome our new investors to our Series A syndicate and acknowledge our current investors for their growing confidence in our technology and approach to empowering the body’s natural defenses against life-threatening solid tumors where there are significant gaps in cell therapies. Our proprietary TAC technology platform offers an innovative approach to developing novel autologous and allogeneic treatments for solid tumors, and we are excited to advance our pipeline through 2022 and beyond," Paul Lammers, Triumvira President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US